Tag: Advanced liver cancer
AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study
AstraZeneca's IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the ... Read More
Phase 3 trial of Pexa-Vec for advanced liver cancer initiated in China
South Korean biotech company SillaJen and Hong Kong-based Lee's Pharmaceutical have enrolled the first patient in China for a phase 3 trial called PHOCUS which ... Read More